News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
NiftyTrader Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Erik Otto, an investor in Chemomab Therapeutics Ltd. (CMMB), has filed an amended Schedule 13G, disclosing beneficial ownership of 90,000 American Depository Shares (ADSs), which represents 1.2% of the company's outstanding ADSs. Each ADS represents twenty ordinary shares. Otto holds sole voting and dispositive …
Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …
Chemomab Therapeutics Ltd (CMMB) has a "Strong Buy" rating based on 2 analysts, with a target price of USD 26.50, representing a potential upside of 733.33%. The company's previous quarter's EPS was USD -0.24, slightly below the market expectation of USD -0.22, with the …
Chemomab Therapeutics (Nasdaq:CMMB) is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory diseases. The company faces significant risks, including a highly volatile share price, shareholder dilution, and projected earnings decline, with recent news dominated by a proposed reverse merger with Scipher …
This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for …
This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. …
This article provides details on the institutional confidence in Chemomab Therapeutics Ltd (CMMB), including its stock performance and key shareholder activities. It lists several institutional and individual shareholders, along with the shares they hold and their percentage change. The stock closed at $1.410 with …
This article provides an overview of Chemomab Therapeutics Ltd (CMMB) stock performance, showing a closing price of $1.360 with a -2.86% change. It highlights that critical revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page …
This article provides historical dividend and stock split information for Chemomab Therapeutics Ltd (CMMB). It notes that no dividends have been distributed over the past five years, but lists several stock splits, including a 4:1 merger in August 2025 and multiple 16:1 mergers in …
This article provides a brief valuation analysis for Chemomab Therapeutics Ltd (CMMB), noting key financial metrics. As of the close on July 24th, CMMB had a market cap of $39.17 million and a P/E TTM of 7.81. However, specific P/E, P/B, and P/CF data …
This article provides a risk assessment for Chemomab Therapeutics Ltd (CMMB), focusing on volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return Best/Worst Daily Return, Sharpe Ratio, Skewness, Realised Volatility, Standardised True Range, Downside …
This article provides financial information for Chemomab Therapeutics Ltd. (NASDAQ: CMMB) on TradingView. It indicates that the market is closed with no recent trades. The content focuses on an overview of financial data, segments, and other fundamental statistics for the company.
This article provides a stock score and comprehensive analysis of Chemomab Therapeutics Ltd (CMMB) from TradingKey. It details how TradingKey generates its stock scores across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. The article states that …
Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced …
Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to FDA alignment for a single pivotal Phase …
HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which includes contingent value rights for current …
Search by ticker symbol or company name and select a result to open its chart.